Other languages Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
4.68 ^USD	-1.89%		+4.46%	+10.90%

Apr. 25	Shareholder Capital asks Vanda Pharma's board to reconsider Future Pak's offer	RE
Apr. 22	Vanda Pharmaceuticals Appeal for Patents on Sleep Drug Declined by US Supreme Court	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Shareholder Capital asks Vanda Pharma's board to reconsider Future Pak's offer	Apr. 25
U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents	Apr. 22
Butler Hall Capital urges Vanda to engage in sales discussions	Apr. 19
Deals of the day-Mergers and acquisitions	Apr. 17
Vanda Pharmaceuticals rejects takeover proposal from Future Pak	Apr. 17
Future Pak, Ltd. cancelled the acquisition of Vanda Pharmaceuticals Inc. from The Vanguard Group, Inc., State Street Corporation, BlackRock, Inc., Dimensional Fund Advisors LP and others.	Apr. 16
Top Midday Gainers	Apr. 03
Vanda Pharmaceuticals Shares Soar After FDA Approval for Bipolar I Disorder Therapy	Apr. 03
Wall Street nach neuen US-Daten schwächer	Apr. 03
Powell Speech Eyed, Intel Weighs on Sentiment as US Equity Futures Waver Premarket	Apr. 03
Sector Update: Health Care	Apr. 03
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday as Bets Lean Towards Smaller Rate Cuts	Apr. 03
Top Premarket Gainers	Apr. 03
Vanda Pharmaceuticals Secures FDA Approval for Bipolar I Disorder Therapy; Shares Rise Pre-Bell	Apr. 03
US FDA approves Vanda's drug for treatment of bipolar disorder	Apr. 02
US FDA approves Vanda's drug for bipolar disorder	Apr. 02
Vanda Pharmaceuticals' Fanapt (Iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder	Apr. 02
Vanda Pharmaceuticals Announces FDA Update for Supplemental NDA for HETLIOZ in the Treatment of Insomnia	Mar. 06
Vanda Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 07
Vanda Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 07

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Other languages

Filters